Metabolic in vivo Models

liver disease models, nonalcoholic steatohepatitis, cirrhosis, HCC, NAFLD, dyslipidemia

Acute and chronic liver diseases are frequent and potentially life threatening for humans. The underlying etiologies are diverse, ranging from viral infections, autoimmune disorders, intoxications to imbalanced diets and others. Animal liver disease models are needed to mimic human liver diseases. WuXi Biology has established multiple animal liver disease models including acute liver injury; obesity related liver damage; nonalcoholic steatohepatitis (NASH); alcoholic steatohepatitis (ASH), liver fibrosis, liver cirrhosis and hepatocellular carcinoma (HCC). These models possess distinct features and etiology of human liver diseases to help evaluate the efficacy of lead compounds in relevant clinical liver diseases. They are designed to better understand the underlying mechanisms for new drugs to be used in the clinic.

Diabetes & Diabetic Complications

Obesity

Dyslipidemia models

Liver injury models

Endpoint Measurements

Diabetes & Diabetic Complications

Spontaneous Diabetes	db/db Mice, ZDF Rats
High-fat Diet Induced Diabetes	Multiple species
Type 1 Diabetes Model	Streptozotocin (STZ) induction
Type 2 Diabetes Model	db/db mouse
Type 2 Diabetes Model	ob/ob mouse
Type 2 Diabetes Model	Zucker diabetic fatty (ZDF) rat
Type 2 Diabetes Model	High-fat diet / STZ induction
Diabetic Nephropathy Model	Streptozotocin (STZ) induction
Diabetic Nephropathy Model	db/db mouse
Diabetic neuropathic pain	Chronic Neuropathic Pain
Diabetic Complications	Retinopathy (retina vascular leakage)
Diabetic Complications	Wound Healing

Obesity

Spontaneous Obesity	(ob/ob Mice, Aged CD-1 Mice, fa/fa Rats)
Foodintake Screening	Mutiple species
Diet Induced Obesity (DIO) Model	High-fat diet (HFD) induction
Diet Induced Obesity (DIO) Model	hGLP1r humanized mouse, high-fat diet (HFD) induction

Dyslipidemia models

Hyperlipidemia Model	High cholesterol diet (HCD) induction
Hyperlipidemia Model	High fat diet/cholesterol/fructose diet (HFD/WD) induction

Liver injury models

Acute liver injury models	Alcohol induced acute liver injury in Kunming mice & NHP
Acute liver injury models	CCl4 induced acute liver injury in rodents & NHP
Chronic liver injury models	CCl4 induced liver fibrosis (mice, rats)
Chronic liver injury models	CCl4 induced liver cirrhosis (mice, rats)
Fibrosis Model	Bile duct ligation (BDL) induced liver fibrosis (mice, rats)
Fibrosis Model	Fatty liver + CCl4 induced liver fibrosis (mice, rats, NHP)
Fibrosis Model	Fatty liver + CCl4 induced liver cirrhosis (mice, rats)
Non-Alcoholic Fatty Liver Disease (NAFLD Model)	High-fat diet (HFD) induction
Non-Alcoholic Steatohepatitis (NASH) Model	High-fat diet (HFD) and carbon tetrachloride (CCL4) induction
Non-Alcoholic Steatohepatitis (NASH) Model	Choline-deficient and high-fat diet (CDHFD) induction
NASH-like Model	Methionine and choline deficient (MCD) diet induction
NASH-like Model	Streptozotocin (STZ) and high-fat diet (HFD) induction
Complicated factor induced chronic liver injury model	High fat diet+alcohol+CCl4 induced liver fibrosis

Endpoint Measurement

Clinical observation and physical examination

Body weight, behavior, food intake, water intake, defecation
Liver weight and spleen weight, ascite measurement, portal vein pressure

Biomarker analysis

Serum ALT / AST analysis
Gene expression and profiling (RT-PCR, microarray gene expression, miRNA)
Protein and metabolite profiling (WB, ELISA, mass spectrometry)
Hepatic hydroxyproline detection

Histology analysis

H&E staining in liver tissues
Sirius red staining and Masson Trchrome staining for collagen deposition and quantification in liver tissue
α-SMA IHC staining and quantification in liver tissues
Other related IHC staining for focused targets and markers